Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2020 16:39 ET | Source: Galera Therapeutics

Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication

-- Evaluates avasopasem manganese’s ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer -- -- Marks expansion of lead product candidate avasopasem manganese...
December 10, 2019 07:00 ET | Source: Galera Therapeutics

Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

- Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds - - Progressed Pivotal Clinical Trial of GC4419 in Head & Neck Cancer with Topline Data...
December 05, 2019 17:18 ET | Source: Galera Therapeutics

Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology

MALVERN, Pa., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
November 06, 2019 19:26 ET | Source: Galera Therapeutics

Galera Therapeutics Announces Pricing of Initial Public Offering

MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...